Federal prosecutors in California are opening a federal probe into Juul Labs; the FDA has approved the first vaccine for smallpox and monkeypox; an analysis from the Congressional Budget Office finds that an approach to address surprise medical bills backed by doctors would cost the government billions.
Amid a rise in the number of vaping-related illnesses and multiple states putting temporarily holds on vaping products, federal prosecutors in California are opening a federal probe into Juul Labs. According to The Wall Street Journal, the investigation is in its early stages and the focus of the probe is unclear. The Federal Trade Commission (FTC), FDA, and multiple state attorneys are also investigating the e-cigarette maker’s marketing practices. The focus of the FTC probe is centered around whether Juul used social media influences and other marketing practices in order to appear to minors and the FDA is conducting a more wide-range investigation, focusing on marketing and outreach, as well as nicotine levels of the refill pods.
The FDA has given the nod to the first live, nonreplicating vaccine to prevent smallpox and monkeypox. The Jynneos Smallpox and Monkeypox Vaccine received approval for the prevention of smallpox and monkeypox in adults aged 18 years or older who are determined to be at high risk for smallpox and monkeypox infection. The vaccine is also part of the Strategies National Stockpile, which is the country’s largest supply of potentially lifesaving treatments and medical supplies for use in a public health emergency severe enough to causes shortages of local supplies.
An approach to curbing surprise medical bills that is backed by doctors groups would increase the deficit by “double digit billions” of dollars, according to an analysis from the Congressional Budget Office. According to The Hill, the approach has the support of doctor and hospital groups that are lobbying hard against leading legislation, arguing it would lead to damaging cuts to their payments. However, the new analysis shows that their favored approach would come with a high price tag while the leading approach would save the government $20 billion over 10 years. The difference between the 2 approaches is regarding how much the insurer would pay a doctor once a patient is protected.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More